Patient Enrollment Started in the Phase II HELIX-2 Clinical Trial
Share
Follow Us
Idenix Pharma begins Phase II combination trial to treat hepatitis C virus infection
PBR Staff Writer
Published December 3, 2013
US-based biopharmaceutical company Idenix Pharmaceuticals has started patient enrollment in the Phase II HELIX-2 clinical trial evaluating an all-oral, direct-acting antiviral (DAA) HCV combination therapy of samatasvir, simeprevir and TMC647055 for the treatment of hepatitis c virus (HCV) infection.
Samatasvir is a once-daily pan-genotypic NS5A inhibitor of Idenix; simeprevir is a once-daily NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir; while TMC647055 is a once-daily NS5B non-nucleoside polymerase inhibitor boosted with low-dose ritonavir developed by Janssen.
Continue reading this entire article:
http://clinicaltrials.pharmaceutical-business-review.com/news/idenix-pharma-begins-phase-ii-combination-trial-to-treat-hepatitis-c-virus-infection-031213-4139779
